Recursion Pharmaceuticals, Inc. RXRX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 7.2%+2.2pp | 5%— | —— | —— | —— | |
| Operating margin | -881.3%-13.5pp | -867.9%+788pp | -1,656.2%-650pp | -1,005.8%-45.7pp | -960.1%-146pp | |
| Net margin | -842.9%+20.4pp | -863.4%+774pp | -1,637.8%-633pp | -1,004.9%-43.6pp | -961.3%-173pp | |
| EBITDA margin | -754.8%+1.0pp | -755.8%+724pp | -1,479.5%-572pp | -907.8%-28.7pp | -879.1%-127pp | |
| Free cash flow margin | -490.7%+15.8pp | -506.5%+518pp | -1,024.7%-415pp | -609.7%+55.4pp | -665.2%-31.5pp | |
| Returns | ||||||
| Return on equity | -57.2%+2.4pp | -59.5%+31.5pp | -91.1%-4.7pp | -86.3%-0.2pp | -86.1%-24.2pp | |
| Return on assets | -42.3%+1.8pp | -44.1%+23.2pp | -67.3%-4.8pp | -62.5%-0.8pp | -61.7%-17.6pp | |
| Return on invested capital | -118.2%+6.4pp | -124.6%+85.2pp | -209.8%-28.7pp | -181.1%-14.3pp | -166.8%-25.8pp | |
| Efficiency | ||||||
| Asset turnover | 0.1×0.0× | 0.1×0.0× | 0×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Liquidity | ||||||
| Current ratio | 5.5×0.0× | 5.5×+0.9× | 4.6×+1.0× | 3.6×-0.5× | 4.1×+0.3× | |
| Quick ratio | 5.5×0.0× | 5.5×+0.9× | 4.6×+1.0× | 3.6×-0.5× | 4.1×+0.3× | |
| Cash ratio | 5.1×0.0× | 5.1×+0.8× | 4.3×+1.0× | 3.3×-0.3× | 3.6×+0.4× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $1.94-23.4% | $2.53+7.9% | $2.34+6.4% | $2.20-5.0% | $2.32-38.6% | |
| Valuation | ||||||
| Market capitalization | $1.62B-23.8% | $2.13B-0.1% | $2.13B+0.4% | $2.12B-0.2% | $2.13B-19.5% | |
| Enterprise value | $1.04B-29.0% | $1.47B-6.1% | $1.57B-7.8% | $1.7B-2.1% | $1.73B-20.2% | |
| Price / sales | 24.4×-4.1× | 28.5×-20.3× | 48.8×+15.9× | 32.8×-2.7× | 35.6×-9.3× | |
| Price / book | 1.6×-0.3× | 1.9×-0.2× | 2×-0.3× | 2.3×0.0× | 2.3×-0.3× | |
| EV / sales | 15.7×-4.0× | 19.7×-16.1× | 35.8×+9.5× | 26.3×-2.7× | 29×-7.9× | |
| Free cash flow yield | -20.1%-2.3pp | -17.8%+3.2pp | -21%-2.5pp | -18.6%+0.1pp | -18.7%-4.6pp | |
| Earnings yield | -34.5%-4.2pp | -30.3%+3.3pp | -33.6%-3.0pp | -30.6%-3.6pp | -27%-9.5pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Recursion Pharmaceuticals, Inc.'s profit margins?
- Recursion Pharmaceuticals, Inc. (RXRX) runs a 7.2% gross margin and a -881.3% operating margin, with a -842.9% net margin.
- Where do Recursion Pharmaceuticals, Inc.'s ratios come from?
- Every ratio is computed from Recursion Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.